BioSpace News Archive

Q2 Financial and Business Highlights: - Net Sales of $134 Million - Adjusted EBITDA of $24 Million - Paid Off, In Full, Term A Loans - Established New $30 Million Revolving Credit Facility

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced the opening of a new manufacturing facility in Carlsbad, CA that will be dedicated to the production of Quidel’s popular QuickVue® line of products.

Helio Health, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

EssilorLuxottica and CooperCompanies, two of the world’s leading vision care companies, have entered into an agreement to create a 50/50 joint venture for the acquisition of SightGlass Vision, a U.S. based life sciences company focused on developing innovative spectacle lenses to reduce the progression of myopia in children.

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, 2020.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in February:

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, and the executive management team will participate in a fireside chat at the Guggenheim Healthcare Talks | 2021 Oncology Days on February 11, 2021

InnoCare Pharma, a leading biopharmaceutical company, announced the first subject dosed in clinical trial of pan-FGFR inhibitor ICP-192 in the United States.

Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced that the company has executed a binding Heads of Terms agreement with the government of Switzerland to supply six million doses of its protein-based COVID-19 vaccine candidate, NVX-CoV2373, to the country.

IMMUNOPRECISE ANTIBODIES LTD. announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 1,616,293 common shares of the Company, at a price to the public of $13.45 per Common Share, less underwriting discounts and commissions, for gross proceeds to the Company of approximately $21.7 million.